MoneyWorks4Me

Venus Remedies - Quaterly Results

29 Oct 2024 Evaluate
Revenue showed a marginal decline at Rs. 1670.20 millions. For the quarter ended September 2024, as compared to corresponding quarter of last year.Profit for the quarter ended September 2024 rises by 69.91% to Rs. 92.60  millions from Rs. 54.50 millions.Operating profit surged to 209.80 millions from the corresponding previous quarter of 160.60 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 1670.20 1701.90 -1.86 2728.80 2688.20 1.51 5752.10 5376.60 6.98
Other Income 107.10 29.30 265.53 122.70 49.90 145.89 113.20 101.70 11.31
PBIDT 209.80 160.60 30.64 368.20 315.90 16.56 722.00 717.00 0.70
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 209.80 160.60 30.64 368.20 315.90 16.56 722.00 717.00 0.70
Depreciation 61.70 62.10 -0.64 119.30 135.30 -11.83 255.50 313.70 -18.55
PBT 148.10 98.50 50.36 248.90 180.60 37.82 466.50 403.30 15.67
TAX 55.50 44.00 26.14 111.80 82.70 35.19 161.50 113.70 42.04
Deferred Tax 18.30 7.20 154.17 49.20 12.00 310.00 39.30 113.70 -65.44
PAT 92.60 54.50 69.91 137.10 97.90 40.04 305.00 289.60 5.32
Equity 133.70 133.70 0.00 133.70 133.70 0.00 133.70 133.70 0.00
PBIDTM(%) 12.56 9.44 33.12 13.49 11.75 14.82 12.55 13.34 -5.88
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1145.25
Cipla 1359.75
Lupin 2047.20
Zydus Lifesciences 1105.00
View more..